

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-113 (Cancelled)

114. **(Previously Presented)** An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2;
wherein said sequence comprises a K179E SNP.
115. **(Previously Presented)** A composition comprising the polypeptide of claim 114 and at least one excipient.
116. **(Previously Presented)** The composition of claim 115, wherein said excipient is a pharmaceutically acceptable excipient.
117. **(Previously Presented)** The composition of 115, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
118. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 114 and a pharmaceutically acceptable excipient.
119. **(Previously Presented)** The pharmaceutical composition of 118, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

120. **(Previously Presented)** An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a K179E SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
121. **(Previously Presented)** The polypeptide of claim 120, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
122. **(Previously Presented)** The polypeptide of claim 120, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
123. **(Previously Presented)** The polypeptide of claim 120, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
124. **(Previously Presented)** The polypeptide of claim 120, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
125. **(Previously Presented)** A composition comprising the polypeptide of claim 120 and at least one excipient.
126. **(Previously Presented)** The composition of claim 125, wherein said excipient is a pharmaceutically acceptable excipient.
127. **(Previously Presented)** The composition of 125, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

128. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 120 and a pharmaceutically acceptable excipient.
129. **(Previously Presented)** The pharmaceutical composition of 128, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
130. **(Previously Presented)** An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a Q102K SNP.
131. **(Previously Presented)** A composition comprising the polypeptide of claim 130 and at least one excipient.
132. **(Previously Presented)** The composition of claim 131, wherein said excipient is a pharmaceutically acceptable excipient.
133. **(Previously Presented)** The composition of 131, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
134. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 130 and a pharmaceutically acceptable excipient.
135. **(Previously Presented)** The pharmaceutical composition of 134, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

136. **(Previously Presented)** An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a Q102K SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
137. **(Previously Presented)** The polypeptide of claim 136, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
138. **(Previously Presented)** The polypeptide of claim 136, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
139. **(Previously Presented)** The polypeptide of claim 136, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
140. **(Previously Presented)** The polypeptide of claim 136, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
141. **(Previously Presented)** A composition comprising the polypeptide of claim 136 and at least one excipient.
142. **(Previously Presented)** The composition of claim 141, wherein said excipient is a pharmaceutically acceptable excipient.
143. **(Previously Presented)** The composition of 141, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

144. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 136 and a pharmaceutically acceptable excipient.
145. **(Previously Presented)** The pharmaceutical composition of 144, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
146. **(Previously Presented)** An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a Q114H SNP.
147. **(Previously Presented)** A composition comprising the polypeptide of claim 146 and at least one excipient.
148. **(Previously Presented)** The composition of claim 147, wherein said excipient is a pharmaceutically acceptable excipient.
149. **(Previously Presented)** The composition of 147, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
150. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 146 and a pharmaceutically acceptable excipient.
151. **(Previously Presented)** The pharmaceutical composition of 150, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

152. **(Previously Presented)** An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2, wherein said sequence comprises a Q114H SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
153. **(Previously Presented)** The polypeptide of claim 152, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
154. **(Previously Presented)** The polypeptide of claim 152, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
155. **(Previously Presented)** The polypeptide of claim 152, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
156. **(Previously Presented)** The polypeptide of claim 152, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
157. **(Previously Presented)** A composition comprising the polypeptide of claim 152 and at least one excipient.
158. **(Previously Presented)** The composition of claim 157, wherein said excipient is a pharmaceutically acceptable excipient.
159. **(Previously Presented)** The composition of 157, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

160. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 152 and a pharmaceutically acceptable excipient.
161. **(Previously Presented)** The pharmaceutical composition of 160, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
162. **(Previously Presented)** An isolated polypeptide comprising:
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a V127D SNP.
163. **(Previously Presented)** A composition comprising the polypeptide of claim 162 and at least one excipient.
164. **(Previously Presented)** The composition of claim 163, wherein said excipient is a pharmaceutically acceptable excipient.
165. **(Previously Presented)** The composition of 163, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.
166. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 162 and a pharmaceutically acceptable excipient.
167. **(Previously Presented)** The pharmaceutical composition of 166, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

168. **(Previously Presented)** An isolated polypeptide comprising an amino acid sequence at least 95% identical to
- a) the amino acid sequence of SEQ ID NO. 2 or
 - b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2; wherein said sequence comprises a V127D SNP and said polypeptide exhibits at least one antiviral, antiproliferative, or immunomodulatory activity.
169. **(Previously Presented)** The polypeptide of claim 168, wherein said amino acid sequence is at least 97% identical to the amino acid sequence SEQ ID NO: 2.
170. **(Previously Presented)** The polypeptide of claim 168, wherein said amino acid sequence is at least 99% identical to the amino acid sequence SEQ ID NO: 2.
171. **(Previously Presented)** The polypeptide of claim 168, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
172. **(Previously Presented)** The polypeptide of claim 168, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO. 2.
173. **(Previously Presented)** A composition comprising the polypeptide of claim 168 and at least one excipient.
174. **(Previously Presented)** The composition of claim 173, wherein said excipient is a pharmaceutically acceptable excipient.
175. **(Previously Presented)** The composition of 173, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

176. **(Previously Presented)** A pharmaceutical composition comprising the polypeptide of claim 168 and a pharmaceutically acceptable excipient.
177. **(Previously Presented)** The pharmaceutical composition of 176, wherein said excipient is a buffer, aqueous vehicle, non-aqueous vehicle, wetting agent, dispersant, emulsifier, or preservative.

Claims 178-193 **(Cancelled)**